Subscribe
shutterstock_1436567156_jonathan_weiss
Jonathan Weiss / Shutterstock.com
13 December 2022AmericasStaff Writer

Third Circuit backs pharma firm in antitrust clash

Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Zydus challenges ruling in Takeda antitrust dispute
16 June 2022   Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.
Americas
Takeda, Arbor aim to stop Turkish copies of high blood pressure drug
22 March 2022   Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Zydus challenges ruling in Takeda antitrust dispute
16 June 2022   Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.
Americas
Takeda, Arbor aim to stop Turkish copies of high blood pressure drug
22 March 2022   Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.

More on this story

Big Pharma
Zydus challenges ruling in Takeda antitrust dispute
16 June 2022   Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.
Americas
Takeda, Arbor aim to stop Turkish copies of high blood pressure drug
22 March 2022   Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?